Biotech is in the doldrums. The SPDR S&P Biotech ETF  declined 18% in the past six months, and money continues to flow out of the sector. While several biotechs managed to IPO in September and October , it's not all roses. ADC Therapeutics pulled its plans to list citing market...

Amgen ( AMGN ) presented results at the 2019 European Society for Medical Oncology ((ESMO)). It presented results from its phase 1 study using AMG 510 to treat patients with a few solid tumors. Specifically, these were in colorectal cancer, appendiceal cancer, and prior reported non-small ...

Welcome to the September review of DivGro, my portfolio of dividend growth stocks. The goal of these monthly reviews is to share updates I've made to the portfolio and to provide a summary of dividends collected. Additionally, I look at how the month's activities have impacted DivGro's project...